The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial

Trial Profile

The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms IMPROVE
  • Sponsors Roche
  • Most Recent Events

    • 17 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Planned end date changed from 1 Jul 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top